Corporate

XVIVO  is a medical technology company which develops and markets solutions and systems for assessing the usability of organs, and maintaining organs in good condition outside the body pending transplantation.

Currently, the company’s products PERFADEX® Plus have a market share of approximately 90 percent in the traditional preservation of lungs for transplantation. The company’s products XPS™ and STEEN Solution™ for warm perfusion have regulatory approval in all major markets, and are the first products for warm perfusion of marginal lungs to have received regulatory approval from the FDA (PMA approval), for use in flushing and temporary continuous normothermic machine perfusion of initially unacceptable excised donor lungs during which time the ex vivo function of the lungs can be reassessed for transplantation.

XVIVO employs approximately 140 people at its headquarters in Gothenburg, Sweden, its office in Lund, Sweden, Groningen, The Netherlands, Milan, Italy and its offices in Denver and Philadelphia, USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO.